Results 101 to 110 of about 270,121 (117)

Modelling the gamma-ray morphology of HESSJ1804−216 from two supernova remnants in a hadronic scenario

Monthly Notices of the Royal Astronomical Society, 2022
Kirsty Feijen, S Einecke, G Rowell
exaly  

Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trial

EClinicalMedicine, 2023
exaly  

MDCO-216 Does Not Induce Adverse Immunostimulation, in Contrast to Its Predecessor ETC-216

Cardiovascular Drugs and Therapy, 2017
Joannes A A Reijers, J Wouter Jukema, Jacobus Burggraaf   +2 more
exaly  

Preclinical and Clinical Pharmacology of DOV 216,303, a “Triple” Reuptake Inhibitor

CNS Neuroscience & Therapeutics, 2006
Piotr Popik, Pal Czobor
exaly  

3D plausible orbital stability close to asteroid (216) Kleopatra

Monthly Notices of the Royal Astronomical Society, 2015
T G G Chanut, O C Winter, A Amarante
exaly  

DOV 216,303, a “Triple” Reuptake Inhibitor: Safety, Tolerability, and Pharmacokinetic Profile

Journal of Clinical Pharmacology, 2004
Pal Czobor
exaly  

The novel 5‐HT1A receptor antagonist, SDZ 216–525, decreases 5‐HT release in rat hippocampus in vivo

British Journal of Pharmacology, 1993
Trevor Sharp, R Mcquade, J R Fozard
exaly  

Circulating microRNA 216 as a Marker for the Early Identification of Severe Acute Pancreatitis

American Journal of the Medical Sciences, 2017
Li-Hui Deng, Na Shi, Zi-Qi Lin
exaly  

SDZ 216–525, a selective and potent 5-HT1A receptor antagonist

European Journal of Pharmacology, 1993
Philippe Schoeffter, John R Fozard, Daniel Höyer   +2 more
exaly  

The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: A microdialyis study in olfactory bulbectomized rats

Pharmacology Biochemistry and Behavior, 2011
Berend Olivier, S Mechiel Korte
exaly